Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05100420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

Study acronym: HiRO-HCM
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years 10 months later Feb 23, 2026 → Dec 31, 2030
See other at-risk trials from Montreal Heart Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Feb 23, 2026 to Dec 31, 2030 Show 5 more changesShow less
    • Trial status changed: Enrolling by Invitation → Recruiting
    • Trial sites expanded: 13 → 17 locations
    • Study completion pushed from Aug 23, 2027 to Dec 31, 2035
    • Eligibility criteria expanded, about 17 words
    • Study description expanded, about 6 words
  2. Study sites: 11 to 13v5
  3. Study sites revised (11)v4
  4. Study sites: 5 to 11v3
  5. Study sites: 1 to 5v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic Cardiomyopathy registry, biobank and imaging data repository (HiRO-HCM) is a multicenter study that will prospectively enroll patients with HCM as well as those carrying sarcomeric gene variants predisposing to HCM. The objectives of HiRO-HCM are: 1. to better understand the natural history of the disease and identify clinical markers and biomarkers for adverse outcomes; 2. to derive and validate risk prediction models for disease expression, complications and response to therapy; 3. to better define the genetic architecture of sarcomeric and non-sarcomeric HCM.
Trial Details
NCT Number NCT05100420
Lead Sponsor Montreal Heart Institute
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions
(from sponsor)		 Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Cardiomyopathies
Related terms Cardiomyopathies, Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial, Death, Sudden, Cardiac
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov